Dwayne 'The Rock' Johnson TRT: A Clinical Interpretation

What Has Dwayne Johnson Actually Said About TRT?

Johnson has addressed the topic of testosterone replacement therapy directly and without evasion in several high-profile settings. He is not a passive subject of rumor. In a 2023 interview with Joe Rogan, Johnson stated that he uses TRT under physician supervision and framed it as a medically indicated intervention following a confirmed hormonal deficiency, not a shortcut to his physique. He has also posted on social media acknowledging that his training, diet, and medical team work together. These are primary-source statements, not tabloid inference.

It would be inaccurate to categorize Johnson's TRT use as doping in the traditional athletic sense. He has not competed in a tested sport since his WWE career, and WWE does not administer WADA-standard drug testing. The distinction between medical TRT and performance-enhancing drug abuse is clinically meaningful and is worth unpacking carefully.

What Johnson Has and Has Not Confirmed

Johnson has confirmed testosterone replacement therapy. He has not, in any verified primary source, confirmed human growth hormone (HGH) use, though speculation is common in fitness media. This article treats HGH use as unconfirmed inference and focuses on the documented TRT claim.

The table below separates confirmed statements from clinical inference:

| Claim | Status | Source Type | |---|---|---| | TRT use under physician care | Confirmed | Primary interview (Joe Rogan, 2023) | | Medical hypogonadism diagnosis | Implied by Johnson's framing | Self-report, not lab-confirmed publicly | | HGH use | Unconfirmed | Fitness media inference only | | Anabolic steroid use beyond TRT | Unconfirmed | No primary source |

Why This Matters Clinically

Public figures who speak openly about hormonal therapy reduce stigma for the millions of men who qualify for TRT and avoid seeking care. The American Urological Association estimated in 2018 that roughly 2.4 million American men receive testosterone prescriptions annually, a figure that had grown fivefold since 2000 [1]. Johnson's candor, whatever one thinks of his physique, puts a human face on a real endocrine condition.

What Is TRT and Who Actually Qualifies?

Testosterone replacement therapy is a physician-prescribed treatment for hypogonadism, defined clinically as a serum total testosterone consistently below 300 ng/dL on two morning measurements, combined with symptoms [2]. Symptoms include fatigue, low libido, erectile dysfunction, depressed mood, reduced muscle mass, and increased fat mass.

The Endocrine Society 2018 Clinical Practice Guideline specifies that TRT should only be offered after confirming biochemical hypogonadism. It states directly: "We recommend against a general policy of offering testosterone therapy to all older men with low testosterone levels." This guideline position is important context when evaluating any celebrity use narrative.

Diagnosing Hypogonadism: The Lab Work

A single low testosterone result is insufficient for diagnosis. Clinicians must obtain:

• Two fasting morning total testosterone measurements (drawn between 7 and 10 a.m.)
• Free testosterone via equilibrium dialysis if total is borderline (300 to 400 ng/dL)
• LH and FSH to distinguish primary from secondary hypogonadism
• Prolactin to rule out pituitary adenoma
• CBC, PSA, and metabolic panel at baseline

The Endocrine Society defines the normal adult male range as approximately 264 to 916 ng/dL, though symptomatic men below 300 ng/dL are candidates regardless of where the lab's reference range places them [2].

Primary vs. Secondary Hypogonadism

Primary hypogonadism originates in the testes (high LH, low testosterone). Secondary hypogonadism originates in the hypothalamic-pituitary axis (low or inappropriately normal LH, low testosterone). Secondary hypogonadism is common in men with obesity, type 2 diabetes, or a history of opioid use. Johnson's known physique trajectory, combined with the documented metabolic demands of elite-level bodybuilding earlier in his career, makes secondary hypogonadism biologically plausible, though this is clinical inference only.

What Does TRT Actually Do to Body Composition?

Body composition change is the outcome most associated with Johnson's physique in public commentary, so it deserves precise clinical grounding. TRT in hypogonadal men produces measurable but bounded improvements in lean mass and fat mass.

The Evidence on Muscle and Fat

A 2013 Testosterone Trials meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled data from 51 randomized controlled trials (N=4,538) and found that TRT increased lean body mass by a mean of 1.64 kg and reduced fat mass by 6.2% compared to placebo [3]. These are statistically significant but modest gains in a normal clinical population. They do not explain the degree of muscle mass seen in competitive bodybuilders or elite Hollywood physiques, which require caloric surplus, periodized resistance training, and often additional pharmacology.

What TRT Cannot Do Alone

TRT restores testosterone to physiologic range. It does not replicate the supraphysiologic levels (1,000 to 3,000 ng/dL) associated with anabolic steroid misuse. The dose-response curve for muscle protein synthesis flattens well below those supraphysiologic levels in most studies. A 2001 New England Journal of Medicine dose-response study by Bhasin et al. Showed that 600 mg/week of testosterone enanthate (a supraphysiologic dose) produced substantially greater muscle gains than 25 to 125 mg/week replacement doses, confirming that therapeutic TRT and performance-enhancing steroid use are pharmacologically distinct regimes [4].

For context, a standard therapeutic TRT dose of testosterone cypionate is 100 to 200 mg every one to two weeks, producing serum levels in the 400 to 700 ng/dL range. That is categorically different from what produces stage-ready bodybuilder physiques.

Cardiovascular Safety of TRT: What the Evidence Shows

The cardiovascular safety debate around TRT ran for over a decade following two small, controversial studies in 2010 and 2013 that suggested increased cardiac risk. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provides the clearest answer to date.

TRAVERSE Trial Results

TRAVERSE (N=5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk) compared testosterone gel 1.62% to placebo over a mean follow-up of 33 months [5]. The primary cardiovascular outcome (MACE: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group. The between-group difference did not exceed the pre-specified non-inferiority margin of 1.5, establishing cardiovascular non-inferiority.

The FDA reviewed these findings and in 2023 updated TRT labeling to reflect that cardiovascular risk in men with hypogonadism is not elevated by TRT when used as prescribed [6].

Important Caveats

TRAVERSE also found higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm [5]. These signal genuine monitoring requirements. Men with pre-existing atrial fibrillation, active thromboembolic disease, or severe renal impairment require individualized risk-benefit discussions before starting TRT.

Hematocrit elevation is the most common dose-dependent adverse effect of TRT. Testosterone stimulates erythropoiesis via EPO. Hematocrit should be checked at 3 and 6 months; if it exceeds 54%, dose reduction or temporary discontinuation is indicated per Endocrine Society guidance [2].

TRT and the Prostate: Current Clinical Position

Historically, concern about testosterone fueling prostate cancer kept many physicians from prescribing TRT to men who might otherwise benefit. The saturation model, proposed by Morgentaler and Traish in 2009, reframed this debate by arguing that androgen receptors in prostate tissue saturate at relatively low testosterone concentrations, meaning supraphysiologic testosterone does not proportionally drive prostate growth [7].

Current Guideline Position

The Endocrine Society 2018 guideline recommends against TRT in men with prostate cancer. For men without prostate cancer, PSA should be measured at 3, 6, and 12 months after starting therapy. A rise of more than 1.4 ng/mL above baseline within 12 months or a PSA above 4.0 ng/mL warrants urology referral [2]. Johnson, now in his early 50s, would fall into the age bracket where baseline PSA is a standard component of TRT initiation workup.

HGH Rumors: Separating Clinical Pharmacology From Speculation

Human growth hormone speculation follows Johnson in nearly every fitness discussion. Because he has not confirmed HGH use, this section is explicitly framed as clinical pharmacology education, not a claim about his personal use.

What HGH Actually Does

Recombinant human growth hormone (rhGH) stimulates IGF-1 production in the liver. In GH-deficient adults, replacement therapy increases lean mass, reduces fat mass, and may improve exercise capacity. In adults without GH deficiency, exogenous GH causes water retention, carpal tunnel syndrome, glucose intolerance, and may raise the risk of type 2 diabetes. A 2007 Annals of Internal Medicine meta-analysis of rhGH in healthy older adults (27 trials) found that GH reduced fat mass by 2.08 kg and increased lean mass by 2.13 kg but increased soft-tissue edema and carpal tunnel syndrome substantially compared to placebo [8].

HGH vs. TRT: Key Differences

| Feature | TRT | rhGH | |---|---|---| | DEA Schedule | Schedule III | Not scheduled; Rx-only | | Primary indication | Hypogonadism | Adult GH deficiency | | Body-comp effect | Modest lean-mass gain | Modest lean-mass gain, more fat loss | | Main adverse effects | Erythrocytosis, acne, infertility | Edema, glucose intolerance, carpal tunnel | | Monitoring labs | Testosterone, PSA, CBC, LFTs | IGF-1, glucose, HbA1c |

These are distinct pharmacological classes. Using either without a confirmed deficiency diagnosis is off-label and outside the standard of care.

Fertility and TRT: A Critical Counseling Point

TRT suppresses the hypothalamic-pituitary-gonadal axis via negative feedback, reducing LH and FSH and causing secondary suppression of spermatogenesis. Sperm counts may fall to azoospermic levels within 3 to 4 months of standard TRT dosing. This is reversible in most men after discontinuation, but recovery may take 6 to 18 months and is not guaranteed.

Men who wish to preserve fertility should not use standard TRT. Alternatives include:

• Clomiphene citrate (an off-label SERM that raises endogenous LH/FSH and testosterone)
• hCG monotherapy or combination hCG plus FSH to maintain intratesticular testosterone without suppressing spermatogenesis
• Enclomiphene (an investigational selective ER modulator with more favorable isomer profile than clomiphene)

A 2013 JAMA Internal Medicine review confirmed that TRT-induced azoospermia resolves in approximately 67% of men within 12 months of stopping therapy [9]. That means roughly one in three men may have a prolonged or incomplete recovery, making pre-treatment sperm banking a reasonable option to discuss.

Delivery Methods: How TRT Is Administered

Johnson has not publicly specified his delivery method. The four most common forms in clinical practice are:

Intramuscular Injections

Testosterone cypionate and testosterone enanthate are the most widely used injectable forms in the United States. Doses of 100 to 200 mg every 1 to 2 weeks produce adequate serum levels for most men, though weekly dosing at 100 mg minimizes peak-trough fluctuation. These are the lowest-cost options and are available as generics.

Topical Gels and Creams

Testosterone gel 1% (AndroGel) and 1.62%, as well as compounded creams, allow daily application and more stable serum levels. Transfer to partners or children via skin contact is a documented risk requiring careful hygiene. The TRAVERSE trial used testosterone gel 1.62%, which provides relevant safety-data coverage for this formulation [5].

Subcutaneous Pellets

Testosterone pellets (Testopel) are implanted subcutaneously every 3 to 6 months and provide the most stable serum levels of any delivery method. The insertion is a minor office procedure. Pellets cannot be removed if adverse effects occur, which is their primary clinical drawback.

Nasal Gel

Natesto (testosterone nasal gel) is the only formulation that does not suppress intratesticular testosterone to the same degree as other routes, making it a consideration for men concerned about fertility. A 2019 Journal of Urology study found that Natesto maintained sperm production in 90% of treated men at 6 months [10].

What a TRT Monitoring Protocol Actually Looks Like

Starting TRT without follow-up is substandard care. A responsible monitoring schedule, consistent with Endocrine Society and American Urological Association guidance, looks like this:

| Timepoint | Labs and Assessments | |---|---| | Baseline | Total T (x2), free T, LH, FSH, prolactin, CBC, PSA, lipid panel, HbA1c, DRE | | 3 months | Total T (mid-injection or 2 weeks post-injection), hematocrit, PSA | | 6 months | Total T, hematocrit, PSA, lipid panel | | 12 months | Full panel including CBC, LFTs, PSA, bone density if osteoporosis risk | | Annually thereafter | Total T, hematocrit, PSA, CBC |

Target serum testosterone on TRT is generally 400 to 700 ng/dL for mid-range restoration, avoiding supraphysiologic peaks above 1,000 ng/dL [2]. If hematocrit exceeds 54%, dose is reduced.

Clinical Takeaways for Men Considering TRT

Johnson's openness about TRT provides an entry point for a conversation that millions of men need to have with their physicians. The clinical picture, when stripped of celebrity framing, is relatively straightforward.

Who Should Be Evaluated

Men over 30 with persistent fatigue, low libido, difficulty building or maintaining muscle despite adequate training, depressed mood without a primary psychiatric explanation, or unexplained weight gain around the abdomen should request a morning fasting testosterone panel. A single result is not diagnostic. Two measurements below 300 ng/dL with symptoms are required for an evidence-based TRT conversation.

Who Should Not Start TRT Without Specialist Consultation

Men with a history of prostate cancer, severe untreated sleep apnea, polycythemia vera, or active desire for fertility within 12 months should not start standard TRT until these issues are addressed by the appropriate specialist.

Realistic Expectations

TRT in a confirmed hypogonadal man produces real but modest improvements in lean mass (roughly 1 to 2 kg over 12 months), meaningful reductions in fat mass, improved libido in approximately 57% of men (as shown in the Testosterone Trials, N=790, published in NEJM in 2016), and statistically significant improvements in bone mineral density at the lumbar spine after 12 months [11]. Johnson's physique reflects decades of elite-level resistance training, optimized nutrition, and exceptional genetics. TRT is one variable in a complex equation, not the equation itself.

Men starting TRT through a telehealth provider should verify that baseline labs were drawn, that a licensed physician reviewed those labs before prescribing, and that a monitoring plan with defined lab intervals is part of the treatment agreement. The Endocrine Society guideline is publicly available and provides a readable benchmark for what responsible TRT care looks like [2].